Publications

Show Filters

Searches all publications.

Search Term

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-25
    E.g., 2018-02-25

Articles

254624 items
12:00 AM, Feb 28, 1994  |  BC Week In Review | Company News  |  Deals

Energy BioSystems deal

ENBC (The Woodlands, Tex.) and The M. W. Kellogg Co. (Houston) agreed in principle to develop ENBC's biocatalytic desulfurization (BDS) technology to reduce sulfur levels in petroleum streams. Kellogg would provide the basic engineering packages...
12:00 AM, Feb 28, 1994  |  BC Week In Review | Company News  |  Other News

LifeCell other research news

LIFC (The Woodlands, Tex.) received a $65,000 Phase I SBIR from the National Science Foundation to develop reconstituted, full-thickness human skin. The grant will fund a six-month study to optimize conditions for co-culturing human keratinocytes,...
12:00 AM, Feb 28, 1994  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Collagen Corp. (CGEN) Kemper Securities analyst John Boettiger raised his rating to "strong buy" from "long term buy" after lowering it only three weeks previously. Boettiger had lowered the rating in recognition of CGEN's...
12:00 AM, Feb 28, 1994  |  BC Week In Review | Company News  |  Other News

Avid Therapeutics other research news

The National Cancer Institute (NCI) granted the Philadelphia company access to NCI's natural products repository. The repository will provide the company with a wide range of natural products that will be evaluated using Avid's hepatitis...
12:00 AM, Feb 28, 1994  |  BC Week In Review | Company News  |  Deals

Canji Inc. deal

The San Diego company acquired a patented delivery system for gene therapies from American Gene Therapy Inc. (Edmonton, Alberta). Based on the human centromere, a structure composed of DNA that holds chromosomes together, the mammalian...
12:00 AM, Feb 28, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

Argatroban l-arginine derivative thrombin blocker data

Results of a Phase II dose-ranging comparison with heparin in 72 healthy volunteers showed predictable, rapidly reversable action as an anticoagulant, the company announced. TBC declined to release further details of the data. Tests in...
12:00 AM, Feb 28, 1994  |  BC Week In Review | Company News  |  Deals

Biomira deal

Biomira Inc. (BIOMF)   Hoechst AG's Behringwerke subsidiary received a non-exclusive to license BIOMF's breast cancer antibody B27.29 to develop with Behringwerke's Berilux semi-automated analyzer. The Edmonton, Alberta, company, which received an undisclosed licensing fee, will...
12:00 AM, Feb 28, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

Not disclosed data

TELR (Woburn, Mass.) announced results of a Phase I/II trial of a drug treatment for the loss of acuity common with aging, which is currently corrected with reading glasses. A single treatment with the agent,...
12:00 AM, Feb 28, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Cell Pathways regulatory update

Cell Pathways' FGN-1, a small molecule from a group of compounds that have anti-cancer effects in tissue culture and in animals, received orphan drug designation from the FDA to treat the inherited form of colonic...
12:00 AM, Feb 28, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Telios regulatory update

TLIO (San Diego) resubmitted its amended PMA to the FDA for the use of Argidene Gel to treat diabetic foot ulcers. In January the FDA requested additional information showing that TLIO enrolled an adequate cross-section...

Pages